



**HAL**  
open science

## VARIAPSY - Optimisation thérapeutique en neuropsychopharmacologie

Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. VARIAPSY - Optimisation thérapeutique en neuropsychopharmacologie. 2018, Université Paris Descartes, Institut national de la santé et de la recherche médicale - INSERM, Université Paris Diderot - Paris 7. hceres-02031442

**HAL Id: hceres-02031442**

**<https://hal-hceres.archives-ouvertes.fr/hceres-02031442>**

Submitted on 20 Feb 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## REPORT ON THE RESEARCH UNIT:

Therapeutic Optimization in  
Neuropsychopharmacology

## UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:

Université Paris Descartes

Université Paris Diderot

Institut National de la Santé et de la Recherche  
Médicale - INSERM

**EVALUATION CAMPAIGN 2017-2018**  
GROUP D



In the name of Hcéres<sup>1</sup>:

Michel Cosnard, President

In the name of the expert committee<sup>2</sup>:

Radhouane Dallel, Chairman of the  
committee

Under the decree No.2014-1365 dated 14 November 2014,

<sup>1</sup> The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

<sup>2</sup> The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

## UNIT PRESENTATION

<b>Unit name:</b>	Therapeutic Optimization in Neuropsychopharmacology
<b>Unit acronym:</b>	
<b>Requested label:</b>	UMR_S
<b>Application type:</b>	Renewal
<b>Current number:</b>	1144
<b>Head of the unit (2017-2018):</b>	Mr Jean-Louis LAPLANCHE
<b>Project leader (2019-2023):</b>	Mr Jean-Louis LAPLANCHE
<b>Number of teams:</b>	3

## COMMITTEE MEMBERS

<b>Chair:</b>	Mr Radhouane DALLEL, Université Clermont Auvergne
<b>Experts:</b>	Ms Catherine BELZUNG, Université de Tours Mr Olivier FARDEL, Université de Rennes (representative of CNU) Mr Jean-François GHERSI-EGEA, Centre de Recherche en Neurosciences Lyon Ms Catherine LE MOINE, INCIA, Université de Bordeaux (representative of CoNRS) Mr Pierre MARQUET, Université de Limoges (representative of INSERM CSS) Ms Caroline VOULLAC-MENDOZA, Université Bordeaux (supporting personnel)

### HCERES scientific officer:

Ms Céline SOUCHAY

### Representatives of supervising institutions and bodies:

Mrs Jean-Louis BEAUDEUX, Université Paris Descartes

Ms Christine GUILLARD, Inserm

Ms Catherine LABBE-JULLIE, Université Paris Descartes

Mr Matthieu RESCHE-RIGON, Université Paris Diderot

Mr Michel VIDAL, Faculté de Pharmacie de Paris

## INTRODUCTION

### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The unit is located within the Faculty of Pharmacy-Paris Descartes University. This unit was created on January 1<sup>st</sup>, 2014 under the label INSERM/Paris Descartes and Paris Diderot Universities, by merging three teams working on Neuropharmacology. Including 40 permanent persons on its creation, this unit will involve 49 permanent members (about 15 equivalent full time without supporting personnel) for the next contract.

### MANAGEMENT TEAM

The unit will be managed by the current director Mr Jean-Louis LAPLANCHE. The unit will be organized into three teams under the direction of Mr Frank BELLIVIER (head of team 1), Mr Bruno MÉGARBANE (head of team 2) and Mr Xavier DECLÈVES (head of team 3).

### HCERES NOMENCLATURE

SVE5\_3 Génétique médicale, Pharmacologie, Technologie médicales.

### SCIENTIFIC DOMAIN

The unit's main objective is to optimize the monitoring of psychotropic treatments in neuropsychiatric patients. The unit develops basic and clinical research in neuropsychopharmacology using a translational research strategy to bridge the gap between clinic and basic research.

### UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019
<b>Permanent staff</b>		
Full professors and similar positions	9	12
Assistant professors and similar positions	16	15
<i>Hospital practitioners</i>	8	7
Full time research directors (Directeurs de recherche) and similar positions	0	0
Full time research associates (Chargés de recherche) and similar positions	1	1
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	0	1
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	14	20
<b>TOTAL permanent staff</b>	<b>40</b>	<b>49</b>
<b>Non-permanent staff</b>		
Non-permanent professors and associate professors, including emeritus	4	

Non-permanent full time scientists, including emeritus, post-docs	2	
Non-permanent supporting personnel	2	
PhD Students	13	
<b>TOTAL non-permanent staff</b>	<b>21</b>	
<b>TOTAL unit</b>	<b>61</b>	

## GLOBAL ASSESSMENT OF THE UNIT

The unit is one of the few unit in France recognized for its expertise in neuropsychopharmacology in patients. The scientific production of the unit is very good to excellent. Most of the papers are published in highly-ranked specialized journals in the fields of Psychiatry, Emergency Medicine, Pharmacology and Pharmacy, Neurosciences and Toxicology. The unit is excellent in raising funds from national and international public research agencies as well as industrial companies. Several unit members are evaluators for national and international research funding agencies and participate in scientific committees, have been regularly requested by health authorities for specific questions or are consultants for pharmaceutical companies. Members are often invited to give lectures at national as well as international meetings and universities, suggesting that the unit has an excellent national/international visibility. The economic and social environment of the unit is very good to excellent. The contribution of the unit members to teaching and structuration of local academic life is remarkable. Despite the high quality of the scientific output, the unit did not access to very highly-ranked generalist journals. The unit has only one full-time researcher, which is rather few regarding the ambition of the project. The project seems overambitious for the current size of the unit. The unit has hardly attracted any foreign post-doctoral fellow, and not all researchers of the unit are involved in supervising PhD students or post-doctoral fellows.

The evaluation reports of Hceres  
are available online : [www.hceres.com](http://www.hceres.com)

**Evaluation of clusters of higher education and research institutions**  
**Evaluation of higher education and research institutions**  
**Evaluation of research**  
**Evaluation of doctoral schools**  
**Evaluation of programmes**  
**International evaluation and accreditation**



2 rue Albert Einstein  
75013 Paris, France  
T. 33 (0)1 55 55 60 10

[hceres.com](http://hceres.com)

[@Hceres\\_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)